# A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-phase-ii-and-biomarker-study-of-ramucirumab-a-human-monoclonal-antibody/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Andrew X. Zhu,Richard S. Finn,Mary F. Mulcahy,Jayne Gurtler,Weijing Sun,Jonathan D. Schwartz,Rita P. Dalal,Adarsh Joshi,Rebecca R. Hozak,Yihuan Xu,Marek Ancukiewicz,Rakesh K. Jain,F. Warren Nugent,Dan G. Duda,Keith Stuart |
| Citations | 165 |
| DOI | 10.1158/1078-0432.ccr-13-1442 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://clincancerres.aacrjournals.org/content/clincanres/19/23/6614.full.pdf |
| OpenAlex ID | https://openalex.org/W2114012800 |
| PMID | 24088738 |
| Type | article |
| Year | 2013 |

## Paper authors

- [Jonathan D. Schwartz](https://scholariq.org/researchers/jonathan-d-schwartz/)

## Paper journal

- [Clinical Cancer Research](https://scholariq.org/journals/clinical-cancer-research/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Liver physiology and pathology](https://scholariq.org/topics/liver-physiology-and-pathology/)
- [Lymphatic System and Diseases](https://scholariq.org/topics/lymphatic-system-and-diseases/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.